Edition 1 · October 20, 2026
Same Drug, Different Story: How AI Tailors Lung Cancer Advice to Who You Say You Are
On November 14, 2026, the FDA is due to decide on ivonescimab, a lung cancer drug approved in China, given with chemotherapy for EGFR-mutated lung cancer that grew after targeted treatment. Four AI assistants got its approval status right in all 75 answers. But a caregiver heard about side effects in 11 of 13 answers, and an oncologist heard the benefit in 11 of 12. Only 10 of 50 answers to four askers gave both.